A Pittsburgh-based biotech firm has began a one-of-a-kind trial in a affected person with a failing liver. Their aim is to develop a practical second liver throughout the affected person’s physique–one thing by no means achieved earlier than.
If efficient, it is perhaps a life-saving remedy for individuals who require liver transplants however have to attend months for a appropriate donor organ.
LyGenesis is at the moment finishing up a trial in just one affected person with end-stage liver illness (ESLD) to check the efficacy of their allogenic regenerative cell remedy.